Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...

We recently compiled a list of the 10 Firms Buck Market Bloodbath on Monday. In this article, we are going to take a look at ...

J.P. Morgan analyst Brian Cheng maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report) yesterday and set a price target ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its target price boosted by equities researchers at BMO Capital ...

The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.

The joint development project of Protagonist Therapeutics and Johnson & Johnson (NYSE:JNJ) produced Icotrokinra as their ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report)’s stock price reached a new 52-week high on Tuesday after Truist Financial raised their price target on the stock from $60.00 to $76.00.

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Protagonist Therapeutics (PTGX) came out with quarterly earnings of $1.98 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.44 per share a year ago.